#Emergency #response for evaluating #SARS-CoV-2 immune status, #seroprevalence and #convalescent #plasma in #Argentina (PLOS Pathog., abstract)

[Source: PLOS Pathogens, full page: (LINK). Abstract, edited.]

OPEN ACCESS |  PEER-REVIEWED | RESEARCH ARTICLE

Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina

Diego S. Ojeda , María Mora Gonzalez Lopez Ledesma , Horacio M. Pallarés , Guadalupe S. Costa Navarro , Lautaro Sanchez, Beatriz Perazzi, Sergio M. Villordo, Diego E. Alvarez, BioBanco Working Group , Marcela Echavarria, Kasopefoluwa Y. Oguntuyo, Christian S. Stevens, Benhur Lee,  [ … ], Andrea V. Gamarnik

Published: January 14, 2021 | DOI: https://doi.org/10.1371/journal.ppat.1009161

Abstract

We report the emergency development and application of a robust serologic test to evaluate acute and convalescent antibody responses to SARS-CoV-2 in Argentina. The assays, COVIDAR IgG and IgM, which were produced and provided for free to health authorities, private and public health institutions and nursing homes, use a combination of a trimer stabilized spike protein and the receptor binding domain (RBD) in a single enzyme-linked immunosorbent assay (ELISA) plate. Over half million tests have already been distributed to detect and quantify antibodies for multiple purposes, including assessment of immune responses in hospitalized patients and large seroprevalence studies in neighborhoods, slums and health care workers, which resulted in a powerful tool for asymptomatic detection and policy making in the country. Analysis of antibody levels and longitudinal studies of symptomatic and asymptomatic SARS-CoV-2 infections in over one thousand patient samples provided insightful information about IgM and IgG seroconversion time and kinetics, and IgM waning profiles. At least 35% of patients showed seroconversion within 7 days, and 95% within 45 days of symptoms onset, with simultaneous or close sequential IgM and IgG detection. Longitudinal studies of asymptomatic cases showed a wide range of antibody responses with median levels below those observed in symptomatic patients. Regarding convalescent plasma applications, a protocol was standardized for the assessment of end point IgG antibody titers with COVIDAR with more than 500 plasma donors. The protocol showed a positive correlation with neutralizing antibody titers, and was used for clinical trials and therapies across the country. Using this protocol, about 80% of convalescent donor plasmas were potentially suitable for therapies. Here, we demonstrate the importance of providing a robust and specific serologic assay for generating new information about antibody kinetics in infected individuals and mitigation policies to cope with pandemic needs.

Author summary

The development of robust and specific serologic assays to detect antibodies to SARS-CoV-2 is essential to understand the pandemic evolution and establish mitigation strategies. Here, we report the emergency development, production and application of a versatile ELISA test for detecting antibodies against the whole spike protein and its receptor binding domain. Over half million tests have been freely distributed in public and private health institutions of Argentina for evaluating immune responses, convalescent plasma programs and for large seroprevalence studies in neighborhoods and health care workers. We are still learning how and when to use serologic testing in different epidemiological settings. This program allowed us to produce large amount of high quality data on antibody levels in symptomatic and asymptomatic SARS-CoV-2 infections and generate relevant information about IgM and IgG seroconversion time and kinetics. We also present standardized protocols for antibody quantification as guidance for convalescent donor plasma selection in hospitals throughout the country for compassionate use and clinical trials. Here, we provide a framework for generating widely available tools, protocols and information of antibody responses for pandemic management.

Citation: Ojeda DS, Gonzalez Lopez Ledesma MM, Pallarés HM, Costa Navarro GS, Sanchez L, Perazzi B, et al. (2021) Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog 17(1): e1009161. https://doi.org/10.1371/journal.ppat.1009161

Editor: Michael S. Diamond, Washington University School of Medicine, UNITED STATES

Received: October 15, 2020; Accepted: November 13, 2020; Published: January 14, 2021

Copyright: © 2021 Ojeda et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript.

Funding: The COVIDAR project was funded by the CONICET through the Fondo para la Convergencia Estructural del Mercosur (FOCEM), NIH (NIAID) R01.AI095175 and Agencia Argentina de Promoción Científica y Tecnológica PICT2017-1717 Annex COVID-19 to AVG. Founds were also provided by Fundación Williams and Asociación Civil SAND to AVG for COVIDAR and Serokit production and distribution. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Keywords: SARS-CoV-2; COVID-19; Serology; Seroprevalence; Serotherapy; Brazil.

——

Characteristics of Patients Co-infected with #SARS-CoV-2 and #Dengue Virus, Buenos Aires, #Argentina, March–June 2020 (Emerg Infect Dis., abstract)

[Source: US Centers for Disease Control and Prevention (CDC), Emerging Infectious Diseases Journal, full page: (LINK). Abstract, edited.]

Volume 27, Number 2—February 2021 | Synopsis

Characteristics of Patients Co-infected with Severe Acute Respiratory Syndrome Coronavirus 2 and Dengue Virus, Buenos Aires, Argentina, March–June 2020

Lucila M. Carosella, Daniel Pryluka, Aldo Maranzana, Laura Barcan, Rosana Cuini, Cristina Freuler, Alfredo Martinez, Tomás Rivero Equiza, Carolina Rodriguez Peria, Diego Yahni, Martin E. Stryjewski  , and for the COVIDENGUE Study Group

Author affiliations: Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina (L.M. Carosella, A. Martinez, T. Rivero Equiza, M.E. Stryjewski); Sanatorio Otamendi, Buenos Aires (D. Pryluka); General Hospital de Agudos Parmenio Piñero Gobierno de la Ciudad, Buenos Aires (A. Maranzana); Hospital Italiano de Buenos Aires, Buenos Aires (L. Barcan); Hospital de Agudos Dr. Teodoro Álvarez, Buenos Aires (R. Cuini); Hospital Alemán, Buenos Aires (C. Freuler); Sanatorio de Los Arcos, Buenos Aires (C. Rodriguez Peria),; Sanatorio Mutual del Transporte Automotor, Buenos Aires (D. Yahni)

Abstract

An epidemic of dengue virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infections occurred in Argentina during 2020. We describe the clinical characteristics and outcomes in a cohort of patients hospitalized because of co-infection. We retrospectively identified 13 patients from different hospitals in Buenos Aires who had confirmed infection with SARS-CoV-2 and dengue virus and obtained clinical and laboratory data from clinical records. All patients had febrile disease when hospitalized. Headache was a common symptom. A total of 8 patients had respiratory symptoms, 5 had pneumonia, and 3 had rash. Nearly all patients had lymphopenia when hospitalized. No patients were admitted to an intensive care unit or died during follow up. Co-infection with SARS-CoV-2 and dengue virus can occur in patients living in areas in which both viruses are epidemic. The outcome of these patients did not seem to be worse than those having either SARS-CoV-2 or dengue infection alone.

Keywords: SARS-CoV-2; COVID-19; Dengue fever; Argentina.

——

LMB-1 producing #Citrobacter freundii from #Argentina, a novel player in the field of MBLs (Int J Antimicrob Agents, abstract)

[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]

Int J Antimicrob Agents. 2019 Nov 27. pii: S0924-8579(19)30328-0. doi: 10.1016/j.ijantimicag.2019.11.014. [Epub ahead of print]

LMB-1 producing Citrobacter freundii from Argentina, a novel player in the field of MBLs.

Dabos L1, Rodriguez CH2, Nastro M2, Dortet L3, Bonnin R4, Famiglietti A2, Iorga BI5, Vay C2, Naas T6.

Author information: 1 EA7361 “Structure, dynamic, function and expression of broad spectrum β-lactamases”, Paris-Sud University, Faculty of Medicine, Le Kremlin-Bicêtre, France; Joint research Unit EERA « Evolution and Ecology of Resistance to Antibiotics », Institut Pasteur-APHP-University Paris Sud, Paris, France. 2 Departamento de Bioquímica Clinica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina. 3 EA7361 “Structure, dynamic, function and expression of broad spectrum β-lactamases”, Paris-Sud University, Faculty of Medicine, Le Kremlin-Bicêtre, France; Joint research Unit EERA « Evolution and Ecology of Resistance to Antibiotics », Institut Pasteur-APHP-University Paris Sud, Paris, France; Department of Bacteriology-Hygiene, Bicêtre Hospital, APHP, Le Kremlin-Bicêtre, France; French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France. 4 EA7361 “Structure, dynamic, function and expression of broad spectrum β-lactamases”, Paris-Sud University, Faculty of Medicine, Le Kremlin-Bicêtre, France; Joint research Unit EERA « Evolution and Ecology of Resistance to Antibiotics », Institut Pasteur-APHP-University Paris Sud, Paris, France; French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France. 5 CNRS, UMR3525, Paris, France. 6 EA7361 “Structure, dynamic, function and expression of broad spectrum β-lactamases”, Paris-Sud University, Faculty of Medicine, Le Kremlin-Bicêtre, France; Joint research Unit EERA « Evolution and Ecology of Resistance to Antibiotics », Institut Pasteur-APHP-University Paris Sud, Paris, France; Department of Bacteriology-Hygiene, Bicêtre Hospital, APHP, Le Kremlin-Bicêtre, France; French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France. Electronic address: thierry.naas@aphp.fr.

 

Abstract

Carbapenemase-producing Enterobacterales expressing OXA-48, KPC, NDM, VIM or IMP enzymes are increasingly reported worldwide. We have characterized LMB-1, a novel metallo-β-latamase (MBL) of Ambler class B3 from Citrobacter freundii 164 (Cf164) clinical isolate from Buenos Aires, Argentina. Cf164 displayed reduced susceptibility to carbapenems but gave inconsistent results with carbapenemase confirmatory tests, suggesting the presence of a weak carbapenemase. Analysis of WGS of Cf164 using Resfinder revealed four β-lactamase genes coding for CTX-M-8, PER-2, TEM-1 and CMY-150, a novel chromosomally-encoded CMY variant. Kinetic parameters of purified CMY-150 did not reveal any carbapenemase activity. However, CMY-150 conferred to E. coli higher MIC values for ceftazidime and aztreonam as compared to CMY-2. The in-house developed β-lactamase search software (ResMINER) in WGS data, revealed a novel subclass B3 MBL named LMB-1. LMB-1 conferred to E. coli, resistance to penicillins, to expanded-spectrum cephalosporins and reduced susceptibility to carbapenems. The blaLMB-1 gene was located on a 176-kb IncA/C2 plasmid. LMB-1 shared 99% of amino acid sequence identity with the MBL encoded in the chromosome of Rheinheimera pacifica, it’s likely progenitor. Despite repeated attempts, LMB-1 could not be purified, thus only specific activities could evidence hydrolysis of carbapenems. Here we report CMY-150, a novel CMY-2 variant that confers increased ceftazidime and aztreonam MICs to E. coli and the first description of LMB-1 in Argentina. This work underlines the need for several CPE confirmatory tests, as this novel enzyme might have been missed using only one.

Copyright © 2019 Elsevier Ltd. All rights reserved.

KEYWORDS: CPE; Carbapenemase; Class B3 MBL; Metallo-beta-lactamase

PMID: 31785341 DOI: 10.1016/j.ijantimicag.2019.11.014

Keywords: Antibiotics; Drugs Resistance; E. Coli; Citrobacter freundii; Carbapenem; Beta-lactams; Argentina.

——

#Congenital #Zika #syndrome in #Argentina: case series study (Arch Argent Pediatr., abstract)

[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]

Arch Argent Pediatr. 2019 Dec 1;117(6):e635-e639. doi: 10.5546/aap.2019.e635.

[Congenital Zika syndrome in Argentina: case series study].

[Article in Spanish]

Pastrana A1, Albarracín M2, Hoffmann M3, Delturco G3, López R3, Gil R3, Guzmán A3, Del Barco M2, Espeche A3.

Author information: 1 Servicio de Neurología, Hospital Público Materno Infantil de Salta, Argentina. analia.pastrana@gmail.com. 2 Servicio de Neonatología, Hospital Público Materno Infantil de Salta, Argentina. 3 Servicio de Neurología, Hospital Público Materno Infantil de Salta, Argentina.

 

Abstract

In 2015, there was an increase in the incidence of congenital microcephaly in newborns in Brazil. Months later, the causal relationship between Zika virus and these findings was discovered. In Argentina, during the first outbreak there were 5 cases of congenital Zika syndrome reported. In 2017, there was a new outbreak which involved Salta province. We describe 2 patients with autochthonous congenital Zika syndrome: one of the babies with severe congenital microcephaly with lissencephaly, calcifications and ventriculomegaly; and another baby with postnatal microcephaly with asymmetric polymicrogyria, calcifications and delayed myelination. The real impact of this disease is still uncertain, so it is necessary an adequate multidisciplinary monitoring of patients exposed to Zika virus to better understand the infection and its natural history.

Sociedad Argentina de Pediatría.

KEYWORDS: Zika virus; congenital Zika syndrome; microcephaly

PMID: 31758900 DOI: 10.5546/aap.2019.e635

Keywords: Zika Virus; Zika Congenital Syndrome; Microcephaly; Pediatrics; Argentina.

——

Relevance of #HTLV1 proviral load in asymptomatic and symptomatic #patients living in #endemic and non-endemic areas of #Argentina (PLOS One, abstract)

[Source: PLOS One, full page: (LINK). Abstract, edited.]

OPEN ACCESS /  PEER-REVIEWED / RESEARCH ARTICLE

Relevance of HTLV-1 proviral load in asymptomatic and symptomatic patients living in endemic and non-endemic areas of Argentina

María Verónica Pineda, María Belén Bouzas, Mirta Remesar, Ariel Fridman, Carlos Remondegui, Lilia Mammana, Natalia Altamirano, Patricia Paradiso, Patricia Costantini, Luciana Tadey, Paula Aulicino, Andrea Mangano

___

Published: November 22, 2019 / DOI: https://doi.org/10.1371/journal.pone.0225596

 

Abstract

HTLV-1 proviral load (pVL) in peripheral blood mononuclear cell (PBMCs) is proposed as a marker of disease progression but its role still remains controversial. The aim of this study was to evaluate the levels of HTLV-1 pVL in symptomatic patients and asymptomatic HTLV-1 carriers. In this cross-sectional study the pVL was measured by Real Time PCR in 102 asymptomatic carriers and 22 symptomatic patients (5ATLL, 15 TSP and 2 uveitis). We observed that the HTLV-1 pVL was significantly higher in symptomatic patients (median = 4.99 log10 HTLV-1 copies /106 PBMCs) compared to asymptomatic HTLV-1 carriers (median = 4.38 log10 HTLV-1 copies /106 PBMCs; p = 0.0030). A wide variation on the HTLV-1 pVL levels among asymptomatic HTLV-1 carriers was observed with some pVL as high as those observed in symptomatic patients. The asymptomatic HTLV-1 carriers were divided according to the place of birth and the highest levels of pVL were detected among patients from endemics areas from the North of Argentina. Our results reinforce the usefulness of the proviral load would be a prognostic marker of HTLV-1 disease progression. Moreover, host, viral or socio-environmental factors cannot be excluded as determinant of high proviral load.

___

Citation: Pineda MV, Bouzas MB, Remesar M, Fridman A, Remondegui C, Mammana L, et al. (2019) Relevance of HTLV-1 proviral load in asymptomatic and symptomatic patients living in endemic and non-endemic areas of Argentina. PLoS ONE 14(11): e0225596. https://doi.org/10.1371/journal.pone.0225596

Editor: Eduardo Anguita, Hospital Clinico Universitario San Carlos, SPAIN

Received: April 1, 2019; Accepted: October 30, 2019; Published: November 22, 2019

Copyright: © 2019 Pineda et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by Fondo Nacional para Ciencia y Tecnología (FONCYT) [grant number PICT 2010-0502], http://www.agencia.mincyt.gob.ar/foncyt.php. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Keywords: Retrovirus; HTLV-1; Argentina.

——-

#Neisseria meningitidis isolated from #patients in #MSMs (Rev Argent Microbiol., abstract)

[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]

Rev Argent Microbiol. 2019 Oct 15. pii: S0325-7541(19)30079-3. doi: 10.1016/j.ram.2019.03.009. [Epub ahead of print]

[Neisseria meningitidis isolated from patients in men who have sex with men].

[Article in Spanish]

García SD1, Sorhuet-Pereira C2, Perazzi BE3, Losada ME3, Cabellos Astorga G3, Casco RH4, Vay CA3, Mollerach ME5, Famiglietti ÁMR3.

Author information: 1 Cátedra de Microbiología Clínica, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina. Electronic address: biosgarcia@yahoo.com.ar. 2 Cátedra de Microbiología, Departamento de Microbiología, Inmunología y Genética, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina. 3 Cátedra de Microbiología Clínica, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina. 4 Programa de ETS, Hospital de Clínicas, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina. 5 Cátedra de Microbiología, Departamento de Microbiología, Inmunología y Genética, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina; CONICET, Buenos Aires, Argentina.

 

Abstract

During the periods 2000-2004 and 2014-2015, Neisseria meningitidis was investigated in men who have sex with men, 1143 and 544 respectively, who consulted in the sexually-transmitted disease program. Prevalence, serogroup distribution and susceptibility to antibiotics were determined. Pharyngeal, rectal and urethral swabs were cultivated on selective Thayer-Martin modified medium. The identification was performed by biochemical tests and mass spectrometry by MALDI-TOF. Serogroups B, C, W and Y were investigated by PCR in 85 isolates recovered from the pharynx belonging to the second period. MICs of penicillin, ceftriaxone, rifampicin, azithromycin and ciprofloxacin were determined for 66 and 102 isolates from periods 1 and 2 respectively, according to CLSI. The prevalence of N. meningitidis was 17.8% and 28.1%, in periods 1 and 2 respectively; the isolates were mainly recovered from the pharynx. The distribution of serogroups was B 31.5%; Y 7.6%; W 3.3% and 9.8% non-capsulated and the rest would belong to other serogroups. Isolates classified as intermediate to penicillin were 34.8% and 63.7% (first and second periods, respectively); moreover, 11.8% of the isolates from the second period were resistant. All isolates were susceptible to ceftriaxone, to ciprofloxacin (except 3 isolates with MIC values between 0.25 and 0.5μg/ml), 3% were resistant to rifampicin and 2% were not susceptible to azithromicin. The prevalence of N. meningitidis carriage in men who have sex with men was high with a high rate of penicillin non-susceptible isolates. B was the prevalent serogroup.

Copyright © 2019 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L.U. All rights reserved.

KEYWORDS: Neisseria meningitidis; Resistance; Resistencia; Serogroup; Serogrupo

PMID: 31628000 DOI: 10.1016/j.ram.2019.03.009

Keywords: Antibiotics; Drugs Resistance; Penicillin; Neisseria meningitidis; Argentina.

——

#Vector competence of #Aedes aegypti for different strains of #Zika virus in #Argentina (PLoS Negl Trop Dis., abstract)

[Source: PLoS Neglected Tropical Diseases, full page: (LINK). Abstract, edited.]

OPEN ACCESS /  PEER-REVIEWED / RESEARCH ARTICLE

Vector competence of Aedes aegypti for different strains of Zika virus in Argentina

Melisa Berenice Bonica  , Silvina Goenaga  , María Laura Martin, Mariel Feroci, Victoria Luppo, Evangelina Muttis, Cintia Fabbri, María Alejandra Morales, Delia Enria, María Victoria Micieli , Silvana Levis

Published: June 12, 2019 / DOI: https://doi.org/10.1371/journal.pntd.0007433

 

Abstract

The importance of Zika virus (ZIKV) has increased noticeably since the outbreak in the Americas in 2015, when the illness was associated with congenital disorders. Although there is evidence of sexual transmission of the virus, the mosquito Aedes aegypti is believed to be the main vector for transmission to humans. This species of mosquito has not only been found naturally infected with ZIKV, but also has been the subject of study in many vector competence assays that employ different strains of ZIKV around the world. In Argentina, the first case was reported in February 2016 and a total of 278 autochthonous cases have since been confirmed, however, ZIKV virus has not been isolated from any mosquito species yet in Argentina. In order to elucidate if Argentinian Ae. aegypti populations could be a possible vector of ZIKV, we conducted vector competence studies that involved a local strain of ZIKV from Chaco province, and a Venezuelan strain obtained from an imported case. For this purpose, Ae. aegypti adults from the temperate area of Argentina (Buenos Aires province) were fed with infected blood. Body, legs and saliva were harvested and tested by plaque titration on plates of Vero cells for ZIKV at 7, 11 and 14 days post infection (DPI) in order to calculate infection, transmission, and dissemination rates, respectively. Both strains were able to infect mosquitoes at all DPIs, whereas dissemination and transmission were observed at all DPIs for the Argentinian strain but only at 14 DPI for the Venezuelan strain. This study proves the ability of Ae. aegypti mosquitoes from Argentina to become infected with two different strains of ZIKV, both belonging to the Asian lineage, and that the virus can disseminate to the legs and salivary glands.

 

Author summary

Zika virus is a flavivirus transmitted by mosquitoes, isolated for the first time in the Ziika Forest in Uganda in 1947 from a rhesus macaque monkey. The disease is usually asymptomatic, but sometimes it causes a mild illness that comes with fever, rash, joint pain, and conjunctivitis. The World Health Organization focused the attention on this virus after the outbreak in the Americas, when the virus was linked to microcephaly and serious neurological diseases, including Guillain-Barré syndrome. Aedes aegypti was incriminated as the main vector of the virus as it was found both naturally and experimentally infected. This mosquito species was declared eradicated in Argentina by 1970 but re-emerged in 1989. Recent studies found a peculiarity in the genetics of Argentinian Ae. aegypti populations that consists in a combination between both subspecies: Ae. aegypti formosus and Ae. aegypti aegypti. Our study tries to elucidate if Ae. aegypti from Argentina are able to transmit the virus in order to add these mosquitoes to the list of possible vectors of ZIKV and, in future prospect, orient to fight the virus by controlling the vector.

___

Citation: Bonica MB, Goenaga S, Martin ML, Feroci M, Luppo V, Muttis E, et al. (2019) Vector competence of Aedes aegypti for different strains of Zika virus in Argentina. PLoS Negl Trop Dis 13(6): e0007433. https://doi.org/10.1371/journal.pntd.0007433

Editor: Paulo Pimenta, Fundaçao Oswaldo Cruz, BRAZIL

Received: December 11, 2018; Accepted: April 15, 2019; Published: June 12, 2019

Copyright: © 2019 Bonica et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript.

Funding: MBB, EM and MVM received funds from the National Agency for the Promotion of Science and Technology of Argentina (ANPCYT) (PICT 2015-0665). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Keywords: Zika Virus; Mosquitoes; Aedes aegypti; Argentina.

——

#Hepatitis A #outbreak affecting men who have sex with men (#MSM) in central #Argentina, occurred in July 2017-April 2018, later than the #European outbreak (J Clin Virol., abstract)

[Source: Journal of Clinical Virology, full page: (LINK). Abstract, edited.]

Journal of Clinical Virology / Available online 31 May 2019 / In Press, Accepted Manuscript

Hepatitis A outbreak affecting men who have sex with men (MSM) in central Argentina, occurred in July 2017-April 2018, later than the European outbreak

Jorge Mariojouls a, Gonzalo Castro a, María Belén Pisano b, Paula Barbero c, Anabella Fantilli b, Mariel Borda a, Fernando Canna a, Gabriela Barbás a, Viviana Ré b

{a} Laboratorio Central, Ministerio de Salud de la Provincia de Córdoba, Argentina; {b}
Instituto de Virología “Dr. J.M.Vanella”, Facultad de Ciencias Médicas, CONICET, Universidad Nacional de Córdoba, Argentina; {c} Area Epidemiología, Ministerio de Salud de la Provincia de Córdoba, Argentina

Received 7 March 2019, Revised 17 May 2019, Accepted 30 May 2019, Available online 31 May 2019. DOI: https://doi.org/10.1016/j.jcv.2019.05.014

 

Highlights

  • A Hepatitis A outbreak among young adult MSM occurred in 2017-2018 in Argentina.
  • HAV genotype IA, strain VRD 521–2016, was the responsible of the outbreak.
  • Reinforce official policy of vaccination in MSM is mandatory.

 

Abstract

Background

During June-2016 – May-2017, several outbreaks of HA were recorded in Europe, especially described in MSM. In our area since July-2017, an increase of hepatitis A (HA) notification was reported.

Objective

In order to understand the unusual increase of cases occurred in the central region of Argentina, the aim of this study was to describe, characterize and contextualize epidemiologically the HA outbreak occurred this area, until April2018.

Study design

HA cases (positive anti-HAV IgM) obtained from the calendar week 29/2017 in which the first case of MSM was recognized were included in our study. HAV RNA detection and molecular characterization was performed from serum samples and / or stool by RT – PCR of VP1 / 2A genomic region (360bp).

Results

Of the 32 cases notified, 87.5% of them were unvaccinated men and 69.6% were MSM (mean age 31.9 years). All MSM associated HAV sequences were genotyped as IA, and clustered with the VRD 521-2016 strain, responsible of causing outbreaks mostly in MSM in Europe since mid-2016.

Conclusion

As a consequence of the implementation of immunization in children, and the improvement in socio-economic, hygienic and sanitation factors, young adults are becoming increasingly susceptible to HAV infections. Here we add evidence in South America to the HA outbreaks described worldwide among young MSM, demonstrating the need to reinforce official policy of vaccination, in this group and adjust epidemiological surveillance, catch-up vaccination for adolescents, young adults and immunosuppressed patients.

Keywords: Hepatitis A – HAV surveillance – outbreak – MSM – genotyping – Argentina

© 2019 Published by Elsevier B.V.

Keywords: Hepatitis A; Argentina.

——

#SME-4-producing #Serratia marcescens from #Argentina belonging to clade 2 of the S. marcescens phylogeny (J Antimicrob Chemother., abstract)

[Source: Journal of Antimicrobial Chemotherapy, full page: (LINK). Abstract, edited.]

SME-4-producing Serratia marcescens from Argentina belonging to clade 2 of the S. marcescens phylogeny

Laura Dabos, Rafael Patiño-Navarrete, Marcela Nastro, Angela Famiglietti, Philippe Glaser, Carlos H Rodriguez, Thierry Naas

Journal of Antimicrobial Chemotherapy, dkz115, https://doi.org/10.1093/jac/dkz115

Published: 16 April 2019

 

Abstract

Background

SME carbapenemases are increasingly reported, especially from North and South America. Here, we describe an SME-4-producing Serratia marcescens(SME-Sm) clinical isolate from Argentina and compare its genome with other SME-Sm and Sm isolates recovered from public databases.

Methods

Sm isolates were characterized by WGS using Illumina technology, susceptibility testing and MIC determination. Carbapenemase activity was revealed by biochemical tests based on imipenem hydrolysis. A whole-genome phylogeny was estimated for all the Sm isolates retrieved from public databases with kSNP3 and a whole-genome phylogenetic analysis based on non-recombinant core SNPs was inferred for Sm complete genomes and for those encoding any blaSME variants.

Results

Sm163 was resistant to amoxicillin, temocillin, aztreonam and carbapenems, remaining susceptible to extended-spectrum cephalosporins. WGS analysis of Sm163 revealed a genome of 5 139 329 bp and a chromosomally encoded blaSME-4 carbapenemase gene located on a genomic island closely related to SmarGI1-1 of Sm N11-02820. Comparison of the Sm genomes revealed that the 14 SME-Sm isolates possess this genomic island inserted at the same loci, that 13/14 belong to clade 1 and that 11/14 form a well-defined subcluster of cluster I of Sm clade 1, while Sm163 belongs to clade 2, suggesting that an SME-encoding genomic island may have been transferred between isolates from different clades.

Conclusions

To the best of our knowledge this is the first report of an SME-4-encoding Smfrom Argentina. The blaSME-4 gene is located on a SmarGI1-1-like genomic island. The genome of Sm163 belongs to clade 2, unlike all the other SME-Smisolates, which belong to clade 1.

Issue Section: ORIGINAL RESEARCH

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Keywords: Antibiotics; Drugs Resistance; Carbapene; Serratia marcescens; Amoxicillin; Temocillin; Aztreonam; Argentina.

—–

Acute Flaccid #Myelitis Associated with #Enterovirus D68 in #Children, #Argentina, 2016 (Emerg Infect Dis., edited)

[Source: US Centers for Disease Control and Prevention (CDC), Emerging Infectious Diseases Journal, full page: (LINK). Edited.]

Volume 25, Number 3—March 2019 / Dispatch

Acute Flaccid Myelitis Associated with Enterovirus D68 in Children, Argentina, 2016

Carolina M. Carballo  , Marcela García Erro, Nora Sordelli, Gabriel Vazquez, Alicia S. Mistchenko, Claudia Cejas, Manlio Rodriguez, Daniel M. Cisterna, Maria Ceclilia Freire, Maria M. Contrini, and Eduardo L. Lopez

Author affiliations: de Niños “Ricardo Gutiérrez,” Buenos Aires, Argentina (C.M. Carballo, M. García Erro, N. Sordelli, A.S. Mistchenko, M. Rodriguez, M.M. Contrini, E.L. Lopez); Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) Hospital, Buenos Aires (G. Vazquez, C. Cejas); Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) “Dr. Carlos G. Malbrán,” Buenos Aires (D.M. Cisterna, M.C. Freire)

 

Abstract

After a 2014 outbreak of severe respiratory illness caused by enterovirus D68 in the United States, sporadic cases of acute flaccid myelitis have been reported worldwide. We describe a cluster of acute flaccid myelitis cases in Argentina in 2016, adding data to the evidence of association between enterovirus D68 and this polio-like illness.

____

We report a cluster of acute flaccid myelitis (AFM) cases in Buenos Aires, Argentina, in 2016. AFM was defined as acute flaccid paralysis (AFP) with magnetic resonance imaging (MRI) showing lesions predominantly affecting the gray matter of the spinal cord (1). We prospectively studied all patients with AFP who were admitted to Hospital de Niños “Ricardo Gutiérrez” in Buenos Aires during April 24–August 24, 2016 under the Argentine National Surveillance Acute Flaccid Paralysis Program for poliovirus as part of the World Health Organization AFP Program in the Americas. We obtained fecal samples or rectal swab specimens, serum samples, nasopharyngeal swab specimens, and cerebrospinal fluid (CSF) samples.

Fecal samples were tested at the National Reference Center for the Argentine National Surveillance Acute Flaccid Paralysis Program for enterovirus, including wild-type and vaccine-derived poliovirus. We screened clinical samples for enterovirus D68 (EV-D68) using a panrhinovirus and enterovirus nested PCR of enterovirus targeting the 5′ untranslated region (2). We purified the amplified products and prepared them for Sanger sequencing. We performed BLAST searches (https://blast.ncbi.nlm.nih.gov/Blast.cgi) of GenBank sequences to identify which picornavirus was present. We obtained viral protein 1 partial sequences as previously described (3). In addition, we studied a wide panel of viruses (parainfluenza virus 1, 2, and 3; influenza A/B; respiratory syncytial virus; adenovirus; metapneumovirus; rhinovirus; varicella zoster virus; herpes simplex virus; cytomegalovirus) by reverse transcription PCR (RT-PCR) and studied bacteria by culture. We performed MRI and electromyography for all patients.

Fourteen children were admitted with AFP during April–August 2016. Six were confirmed to have AFM by case definition; the other 8 had alternative diagnoses, including Guillain-Barré syndrome (3), influenza virus myositis (2), encephalitis by echovirus (in 1 child with Down syndrome), acute transient hip synovitis (1), and transverse myelitis (1). Patients’ clinical, demographic, and outcome findings are shown in Table 1, diagnostic findings in Table 2.

In 4 (66.7%) of 6 patients, we confirmed EV-D68 infection by nested RT-PCR. In 1 patient, enterovirus was detected but not typed; in 1 patient, no agent was detected. All patients had distinctive neuroimaging changes. We followed confirmed AFM cases for 6 months to assess clinical improvement.

The median age of patients with AFM was 3.9 (range 1–5) years; 4 (66.7%) of the 6 were female, and 3 (50%) had a history of asthma. All patients had prodromal signs or symptoms before onset of neurologic symptoms: 100% had upper respiratory tract infection (URTI); 4 (66.7%) had fever: and 1 (16.7%) had vomiting and abdominal pain. Neurologic symptoms appeared 1–11 (median 2) days after URTI symptoms.

Results of hematology and chemistry analysis were normal for 5 (83%) patients. Patient 1 had leukocytosis (leukocytes 18,000 cells/mm3, with 82% neutrophils) and elevated levels of alanine aminotransferase (103 IU/L [reference 10–43 IU/L]), aspartate aminotransferase (97 IU/L [reference 10–35 IU/L]), and creatine kinase (6,591 IU/L [reference 24–170 IU/L]). During follow-up, patient 1 showed an increased creatine kinase level that could not be related to enterovirus infection.

All confirmed AFM case-patients showed T2 gray matter hyperintensity within the spinal cord on MRI. Electromyography showed early signs of denervation and low motor neuron function in all 5 patients in whom the test could be done. Specimen collection was performed 9.5 (range 3–30) days after URTI symptoms started and 7.5 (range 1–18) days after onset of neurologic symptoms.

Results of nested RT-PCR for enterovirus were negative for all CSF samples; results of the respiratory virus panel were negative for all patients. Neither bacteria nor fungus were isolated in blood or CSF samples. Serum PCR to identify herpes simplex virus, varicella zoster virus, and cytomegalovirus also yielded negative results.

Intravenous immunoglobulin was empirically infused in 5 (83%) patients; 2 (33%) received systemic corticosteroids. Three patients required intensive care unit admission. All patients had neurologic sequelae: persisting palsy in >1 limbs and atrophy of muscles with a shortening of limbs. Two patients required chronic noninvasive ventilatory support during 6 months of follow-up. No patients died.

 

Conclusions

AFM has been associated with different etiologic agents (1). EV-D68 is a nonpolio enterovirus characterized by affinity for α2–6-linked sialic acids typically found in the upper respiratory tract, making the respiratory tract the preferred target for EV-D68 replication, unlike most enteroviruses, which replicate in the gut (1,7). Although there is no definitive evidence of causality between EV-D68 and AFM, since the 2014 EV-D68 respiratory outbreak in North America, AFM cases possibly associated with EV-D68 have been reported in the United States, Canada, Australia, Norway, Great Britain, and France (1,4). We report a cluster of AFM associated with EV-D68 in Argentina; another institution in Argentina (Hospital Garrahan) has also reported a case series of AFM (5,6).

The cluster in this report occurred over a 3-month period, during the 2016 autumn–winter season, which is the typical enterovirus season in Buenos Aires. Clinical and neurologic findings were similar to those of cases reported in other countries, including URTI preceding the neurologic features (4,8,9). Patients were admitted with asymmetric, acute, and progressive weakness of limbs; areflexia; and muscle pain. These symptoms have been reported as polio-like syndrome; however, testing and MRI should be performed for multiple viruses, including enteroviruses and EV-D68, to detect distinctive spinal cord lesions. No sensory sensitivity involvement was observed. Two patients had cranial nerve dysfunction. Laboratory findings were similar to those previously described, including CSF abnormalities (1,4,8).

Different hypotheses to explain difficulties in isolation of EV-D68 have been reported (4). It is possible that most of the nasopharyngeal specimens in previous studies and in our cluster were taken after 7 days of URTI, when the viral load is usually low, as reported by Imamura et al. (10). In our case series, enterovirus was identified in respiratory secretions in 5 (83.3%) of 6 patients, even though specimen collection was performed >7 days (mean 9 days) after AFM onset (in 1 patient, viral load was too low for genotyping). The negative nasopharyngeal specimen was collected at 18 days after onset.

Isolation of EV-D68 in fecal samples is uncommon because the virus is both heat and acid labile (1). However, in 2 (33.3%) of our 6 patients, EV-D68 was identified in fecal samples.

Reported rates of CSF detection of known neurotropic enteroviruses, such as polioviruses and enterovirus A71, are as low as 0%–5%, although viruses could be detected in brain or spinal cord tissue (4,11). A recent mouse model of AFM caused by EV-D68 showed that EV-D68 infects anterior horn motor neurons, resulting in motor neuron death (9). In our series, CSF samples tested negative for EV-D68 and other pathogens.

No specific treatment for EV-D68 AFM is available; the US Centers for Disease Control and Prevention recommends only support measures (7,12). Zhang et al. demonstrated that commercial immunoglobulin contained high levels of neutralizing antibodies against EV-D68 strains during the 2014 outbreak in the United States (13). No vaccines are available.

EV-D68 belonging to subclade B3 was identified in our cluster by molecular sequencing. This subclade was associated with EV-D68 circulation in the United States and Europe in 2016 (14).

We show a cluster of AFM associated with EV-D68 in Argentina. Our findings contribute to global evidence of EV-D68 as a possible cause of localized polio-like illness.

___

Dr. Carballo is a pediatric infectious diseases specialist at the Hospital de Niños “Ricardo Gutierrez” in Buenos Aires. Her research interests are pediatric infectious diseases.

 

References

  1. Messacar  K, Abzug  MJ, Dominguez  SR. 2014 outbreak of enterovirus D68 in North America. J Med Virol. 2016;88:739–45.
  2. Casas  I, Klapper  PE, Cleator  GM, Echevarría  JE, Tenorio  A, Echevarría  JM. Two different PCR assays to detect enteroviral RNA in CSF samples from patients with acute aseptic meningitis. J Med Virol. 1995;47:378–85.
  3. Centers for Disease Control and Prevention. Enterovirus D68 (EV-D68) 2014 outbreak strain-specific real-time reverse 327 transcription/polymerase chain reaction (rRT-PCR) assay instructions. 2014 [cited 2017 Jul 14]. http://www.cdc.gov/non-polio-enterovirus/hcp/ev-329 d68-hcp.html
  4. Holm-Hansen  CC, Midgley  SE, Fischer  TK. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis. 2016;16:e64–75.
  5. Pérez  G, Rosanova  MT, Freire  MC, Paz  MI, Ruvinsky  S, Rugilo  C, et al. Unusual increase of cases of myelitis in a pediatric hospital in Argentina [in Spanish] Arch Argent Pediatr. 2017;115:364–9.https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28737865&dopt=AbstractPubMed
  6. Ruggieri  V, Paz  MI, Peretti  MG, Rugilo  C, Bologna  R, Freire  C, et al. Enterovirus D68 infection in a cluster of children with acute flaccid myelitis, Buenos Aires, Argentina, 2016. Eur J Paediatr Neurol. 2017;21:884–90.
    Centers for Disease Control and Prevention. Enterovirus D68. 2016 [cited 2017 May 26]. https://www.cdc.gov/non-polio-enterovirus/about/ev-d68.html
  7. Greninger  AL, Naccache  SN, Messacar  K, Clayton  A, Yu  G, Somasekar  S, et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis. 2015;15:671–82.
  8. Hixon  AM, Yu  G, Leser  JS, Yagi  S, Clarke  P, Chiu  CY, et al. A mouse model of paralytic myelitis caused by enterovirus D68. PLoS Pathog. 2017;13:e1006199.
  9. Imamura  T, Okamoto  M, Nakakita  S, Suzuki  A, Saito  M, Tamaki  R, et al. Antigenic and receptor binding properties of enterovirus 68. J Virol. 2014;88:2374–84.
  10. Kreuter  JD, Barnes  A, McCarthy  JE, Schwartzman  JD, Oberste  MS, Rhodes  CH, et al. A fatal central nervous system enterovirus 68 infection. Arch Pathol Lab Med. 2011;135:793–6.
  11. Rhoden  E, Zhang  M, Nix  WA, Oberste  MS. In vitro efficacy of antiviral compounds against enterovirus D68. Antimicrob Agents Chemother. 2015;59:7779–81.
  12. Zhang  Y, Moore  DD, Nix  WA, Oberste  MS, Weldon  WC. Neutralization of Enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products. J Clin Virol. 2015;69:172–5.
  13. Wang  G, Zhuge  J, Huang  W, Nolan  SM, Gilrane  VL, Yin  C, et al. Enterovirus D68 subclade B3 strain circulating and causing an outbreak in the United States in 2016. Sci Rep. 2017;7:1242.

___

Suggested citation for this article: Carballo CM, García Erro M, Sordelli N, Vazquez G, Mistchenko AS, Cejas C, et al. Acute flaccid myelitis associated with enterovirus D68 in children, Argentina, 2016. Emerg Infect Dis. 2019 Mar [date cited]. https://doi.org/10.3201/eid2503.170897

DOI: 10.3201/eid2503.170897

Original Publication Date: 1/2/2019

Keywords: AFP; AFM; EV-D68; Argentina.

——